• About Us
    • Our Story
    • Values & Commitment
    • Our Process
    • Meet the Team
    • Our Partners
  • Compliance Services
    • Cell & Gene Therapy
    • Pharmaceutical Drugs
    • Medical Devices
    • FDA 483 / Warning Letter
    • US Agent & Official Correspondent
    • Audits
    • Compliance Without the Attorney Fees
    • Dietary Supplement
    • Facility Registration & Listing
    • FDA Compliance
    • Good Supply Practice
    • Modernization of Cosmetics Regulation Act
    • Quality Culture
    • Product Recalls
    • Quality Systems
    • Regulatory Affairs
    • Training
    • Virtual Quality Assurance
  • Expertise
    • Pharmaceutical
    • Medical Devices
    • Clinical
    • Biologics
  • Resources
    • Compliance Insight Blog
    • GXP Infusion
    • Quality Assurance Accreditation
    • Success Stories
    • Videos and Media
    • White Papers And Downloads
  • Search
  • Contact
Compliance Insight
Skip to content
  • About Us
    • Our Story
    • Values & Commitment
    • Our Process
    • Meet the Team
    • Our Partners
  • Compliance Services
    • Cell & Gene Therapy
    • Pharmaceutical Drugs
    • Medical Devices
    • FDA 483 / Warning Letter
    • US Agent & Official Correspondent
    • Audits
    • Compliance Without the Attorney Fees
    • Dietary Supplement
    • Facility Registration & Listing
    • FDA Compliance
    • Good Supply Practice
    • Modernization of Cosmetics Regulation Act
    • Quality Culture
    • Product Recalls
    • Quality Systems
    • Regulatory Affairs
    • Training
    • Virtual Quality Assurance
  • Expertise
    • Pharmaceutical
    • Medical Devices
    • Clinical
    • Biologics
  • Resources
    • Compliance Insight Blog
    • GXP Infusion
    • Quality Assurance Accreditation
    • Success Stories
    • Videos and Media
    • White Papers And Downloads
  • Search
  • Contact

Efforts to evaluate materials in medical devices to address potential safety questions

March 15, 2019by TLM

Share
  • Facebook
  • Twitter
  • LinkedIn
  • Email

 

Click the link below to see the recent statements from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health FDA on how they are going to be evaluating materials in medical devices to address potential safety questions.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633602.htm

Uncategorized

Be in Touch

info@compliance-insight.com
p. 513-860-3512

Corporate Headquarters

497 Circle Freeway Suite 230
Cincinnati, Ohio 45246

Business Hours

Monday – Friday
8:30am EST – 5:30pm EST

Social

© 2025 by Compliance Insight All Rights Reserved | Contact Us

Privacy Policy | Terms of Use | Use of Cookies